PAHC Earnings

PAHC reported its earnings on 2026-05-06, showcasing a revenue of 383.50M against an estimate of 360.92M, resulting in a 6.26% surprise. The EPS was 0.76, surpassing the expected 0.72 by 5.56%. The stock experienced a -26.22% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following PAHC's earnings announcement on 2026-05-06, the stock price moved by -26.22% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, PAHC's stock price tends to shift by an average of -7.64% in the 10 days leading up to earnings and 1.73% in the 10 days following, providing insight into potential market.

For 2026/Q3, analysts estimate PAHC's annual revenue to reach 364.42M, while the EPS is projected at 0.66. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between PAHC's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2026 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, PAHC's stock price typically moves by -7.64% in the 10 days before its earnings and 1.73% in the 10 days after. For the upcoming 2026/Q3 earnings, analysts expect an EPS of 0.66 and revenue of 364.42M.

The earnings call summary presents a mixed picture. Positive elements include increased revenue, EBITDA, and net income guidance, as well as growth in the Animal Health and Mineral Nutrition segments. However, geopolitical volatility, foreign currency losses, and increased interest expenses pose risks. The Q&A section highlighted minimal impact from the Middle East conflict and a conservative guidance approach. Performance Products segment decline and inventory buildup are concerns. Overall, the positive and negative factors balance each other, leading to a neutral stock price prediction.